Manufacturing services provider Proto Labs (NYSE: PRLB) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.4% year on year to $139.3 million. Guidance for next quarter’s revenue was better than expected at $144 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $0.54 per share was 37.8% above analysts’ consensus estimates.

Is now the time to buy Proto Labs? Find out by accessing our full research report, it’s free.

"Protolabs started 2026 very strong, delivering another record revenue quarter. We achieved double‑digit revenue growth, gross margin expansion, and operating expense leverage. These results reflect strong demand for Protolabs' digital manufacturing services, and disciplined execution across the business," said President and Chief Executive Officer Suresh Krishna.

Company Overview

Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs (NYSE: PRLB) offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, Proto Labs’s 4.6% annualized revenue growth over the last five years was tepid. This fell short of our benchmark for the industrials sector and is a tough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Proto Labs’s annualized revenue growth of 3.9% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.

We can dig further into the company’s revenue dynamics by analyzing its most important segments, Injection Molding and CNC Machining , which are 36.7% and 45.4% of revenue. Over the last two years, Proto Labs’s Injection Molding revenue (injection molds and parts) was flat while its CNC Machining revenue (custom CNC-machined parts) averaged 17.9% year-on-year growth.

This quarter, Proto Labs reported year-on-year revenue growth of 10.4%, and its $139.3 million of revenue exceeded Wall Street’s estimates by 3%. Company management is currently guiding for a 6.6% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 5.8% over the next 12 months. Although this projection suggests its newer products and services will catalyze better top-line performance, it is still below average for the sector.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Operating Margin

Proto Labs was roughly breakeven when averaging the last five years of quarterly operating profits, inadequate for an industrials business. This result is surprising given its high gross margin as a starting point.

Analyzing the trend in its profitability, Proto Labs’s operating margin decreased by 3.3 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Proto Labs’s performance was poor no matter how you look at it - it shows that costs were rising and it couldn’t pass them onto its customers.

In Q1, Proto Labs generated an operating margin profit margin of 7.1%, up 3.5 percentage points year on year. The increase was encouraging, and because its operating margin rose more than its gross margin, we can infer it was more efficient with expenses such as marketing, R&D, and administrative overhead.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for Proto Labs, its EPS declined by 2.9% annually over the last five years while its revenue grew by 4.6%. We can see the difference stemmed from higher interest expenses or taxes as the company actually improved its operating margin and repurchased its shares during this time.

Diving into the nuances of Proto Labs’s earnings can give us a better understanding of its performance. As we mentioned earlier, Proto Labs’s operating margin expanded this quarter but declined by 3.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business.

For Proto Labs, its two-year annual EPS growth of 4.6% was higher than its five-year trend. Accelerating earnings growth is almost always an encouraging data point.

In Q1, Proto Labs reported adjusted EPS of $0.54, up from $0.33 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Proto Labs’s full-year EPS of $1.86 to stay about the same.

Key Takeaways from Proto Labs’s Q1 Results

We were impressed by Proto Labs’s optimistic EPS guidance for next quarter, which blew past analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 3.3% to $66.94 immediately following the results.

Proto Labs had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).